| abstract |
"SELECTIVE ANDROGEN RECEPTOR MODULATORS IN NITROGEN BRIDGE AND ITS METHODS OF USE". This invention provides a class of androgen receptor targeting agents (ADRA). The agents define a new subclass of compounds, which are selective androgen receptor modulators (MSRA). Several MSRA compounds have unexpected anabolic and androgenic activity from a non-steroidal androgen receptor ligand. Other MSRA compounds have an unexpected anti-androgenic activity of a non-steroidal androgen receptor ligand. The MSRA compounds, either alone or in a composition, serve for a) male contraception; b) treating a variety of hormone-related conditions, for example conditions associated with Androgen Decline in Male Aging (DAEM), such as fatigue, depression, decreased libido, sexual dysfunction, erectile dysfunction, hypogonadism, osteoporosis, hair loss , anemia, obesity sarcopenia, osteopenia, osteoporosis, benign prostate hyperplasia, changes in mood and cognition, and prostate cancer; c) treatment of conditions associated with Female Androgen Decline (DAF), such as sexual dysfunction, decreased sexual libido, hypogonadism, sarcopenia, osteopenia, osteoporosis, changes in cognition and mood, depression, anemia, hair loss, endometriosis obesity, cancer of the breast, uterine cancer and ovarian cancer; d) treatment and / or prevention of acute or chronic muscle degeneration states; e) prevention and / or treatment of "dry eye" conditions; f) oral androgen replacement therapy; and / or g) decreased incidence by stopping or causing a regression of prostate cancer. |